Efficacy of trifluridine/tipiracil as IV line chemotherapy in a young woman with metastatic colorectal cancer. A case report Case report

##plugins.themes.bootstrap3.article.sidebar##

PDF (English)


Opublikowane: mar 31, 2020
DOI: https://doi.org/10.24292/01.OR.120300320
Słowa kluczowe:
metastatic colorectal cancer, chemotherapy, trifluridine/tipiracil, progression free survival

##plugins.themes.bootstrap3.article.main##

Rafał Wiśniowski
Department of Oncology and Hematology, Beskid Oncology Centre ? John Paul II Memorial City Hospital in Bielsko-Biala

Abstrakt

Colorectal cancer is the most common gastrointestinal malignancy and the third most frequently diagnosed cancer worldwide. Trifluridine/tipiracil represents an approved option for the treatment of advanced metastatic colorectal cancer in patients who are refractory, or are not considered candidates for currently available therapies. We present a case of a young woman with refractory metastatic colorectal cancer treated with this agent as the IV line of chemotherapy in which remarkable prolongation of progression free survival time was observed.

##plugins.generic.usageStats.downloads##

##plugins.generic.usageStats.noStats##

##plugins.themes.bootstrap3.article.details##

Jak cytować
1.
Wiśniowski R. Efficacy of trifluridine/tipiracil as IV line chemotherapy in a young woman with metastatic colorectal cancer. A case report. OncoReview [Internet]. 31 marzec 2020 [cytowane 26 maj 2026];10(1(37):23-6. Dostępne na: https://www.journalsmededu.pl/index.php/OncoReview/article/view/1079
Numer
Tom 10 Nr 1(37) (2020)
Dział
CARDIO-ONCOLOGY

Copyright: ? Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)